Literature DB >> 16248833

Drug therapy in Brugada syndrome.

Manlio F Márquez1, Gabriel Salica, Antonio G Hermosillo, Gustavo Pastelín, Manuel Cárdenas.   

Abstract

Sudden cardiac death in healthy individuals with structurally normal hearts and a characteristic morphology of the QRS complex resembling a right bundle branch block with elevation of the ST segment in V1 to V3 is known as Brugada syndrome (BrS). Although placement of an implantable cardioverter-defibrillator is considered the only effective therapy for symptomatic patients, some authors have repeatedly reported a beneficial effect of quinidine and isoproterenol in patients with BrS. Also, isolated case reports on the usefulness of cilostazol, sotalol, and mexiletine have been described. The present article reviews the mechanisms by which these drugs may act and their role in the pharmacotherapy of BrS. Other possible agents, mainly I(2) blockers, are also reviewed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16248833     DOI: 10.2174/156800605774370353

Source DB:  PubMed          Journal:  Curr Drug Targets Cardiovasc Haematol Disord        ISSN: 1568-0061


  3 in total

Review 1.  Inherited arrhythmic disorders: long QT and Brugada syndromes.

Authors:  Amirali Nader; Ali Massumi; Jie Cheng; Mehdi Razavi
Journal:  Tex Heart Inst J       Date:  2007

Review 2.  Pharmacological Therapy in Brugada Syndrome.

Authors:  Oholi Tovia Brodie; Yoav Michowitz; Bernard Belhassen
Journal:  Arrhythm Electrophysiol Rev       Date:  2018-06

3.  Massive electrical storm at disease onset in a patient with Brugada syndrome.

Authors:  Jannik L Pallisgaard; Uffe Gang; Jørgen K Kanters; Peter R Hansen
Journal:  Am J Case Rep       Date:  2014-12-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.